A bullish thesis on Option Care Health, Inc. argues the stock offers an asymmetric risk-reward opportunity following a roughly 30 percent share price decline driven by Stelara biosimilar disruption. The company is the largest independent provider of home and alternate-site infusion services in the United States, with quarterly revenues in the $1.3 to $1.4 billion range and forward EBITDA margin guidance improving toward about 8.5 percent. The thesis contends that additional biosimilar or self-administration substitution risk is limited until late 2027 to 2028, and the valuation already reflects pessimism with a forward P/E near 11 times and EV/EBITDA around 10 times. Upside catalysts include insider buying, pipeline expansion into neurology, oncology, and rare disease infusibles, and secular tailwinds from the shift to home care, with a base case implying 10 to 35 percent upside and a bull case implying 35 to 50 percent upside over the next one to three quarters.
Option Care Health IncBullish thesis argues asymmetric risk-reward after 30% decline, with valuation at forward P/E ~11x and catalysts including insider buying and pipeline expansion.